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Evaluation of a medication monitor-based
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controlled trial
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Abstract
Background: Treatment for drug-sensitive tuberculosis (TB) is taken for at least 6 months and problems with
adherence are common. Therefore, there is substantial interest in the possible use of eHealth interventions to
support patients to take their treatment. Electronic medication monitors have been shown to improve adherence
to TB medication, but the impact on clinical outcomes is unknown. We aim to evaluate the impact of a medication
monitor-based treatment strategy for drug-sensitive TB patients on a composite poor outcome measured over
18 months from start of TB treatment.
Methods/design: We will conduct an open, pragmatic, cluster randomised superiority trial, with 24 counties/districts
in three provinces in China, randomised 1:1 to implement the intervention or standard of care. Adults (aged ≥ 18 years)
with a new episode of GeneXpert-positive and rifampicin-sensitive pulmonary TB, who plan to be in the study area for
the next 18 months, and will receive daily fixed-dose combination tablets for 6 months of treatment are eligible. The
intervention is centred around a medication monitor that holds a 1-month supply of medication and has three key
functions: as an audio and visual reminder for patients to take their daily medication; reminds patients of upcoming
monthly visit; and records date and time whenever the box is opened. At the monthly follow-up visit, the doctor
downloads these data to generate a graphical display of the last month’s adherence record for discussion with the
patient and potentially to switch the patient to more intensive management. The primary outcome is a composite
poor outcome measured over 18 months from start of TB treatment, defined as either of poor outcome at the end of
treatment (death, treatment failure, or loss to follow-up) or subsequent recurrence (culture positive for TB at 12 or
18 months or re-starting TB treatment in the follow-up period). An economic evaluation will also be conducted as part
of this study.
Discussion: This trial will assess whether a medication monitor-based treatment strategy can improve clinical outcomes
for TB patients. Several trials of other eHealth interventions for TB treatment are ongoing and are summarised in this
paper. This trial will provide an important part of the emerging evidence base for the potential of eHealth to improve TB
treatment outcomes.
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Background
Background and rationale
Tuberculosis (TB) remains one of the world’s deadliest
communicable diseases. In 2015, an estimated 10.4 million
people developed TB and 1.4 million died from the disease
[1]. China accounts for the third highest number of cases
worldwide, with 0.92 million estimated incident cases in
2015 [1]. The World Health Organization (WHO) declared
a global TB control emergency in April 1993, with a global
Directly Observed Treatment Short-course strategy being
proposed as a solution. A key point of this strategy is
directly observed treatment (DOT), designed specifically to
strengthen treatment adherence. The WHO defines DOT
as 6–8 months’ worth of regular treatment for TB patients
who have already been found to be infectious, along with
direct observation of patient drug intake during the inten-
sive phase, at the very least. Implementation of the Directly
Observed Treatment Short-course strategy commenced in
China in 1992 and covered the entire country by 2005 [2].
However, a meta-analysis of studies from China reported
that 52% of the TB patients were on self-administered treat-
ment, 27% were observed by family members and only 20%
were observed by health workers [3]. In the 2010 National
TB Prevalence Survey in China, 20% of TB patients treated
by the public health system – using national TB case-
management approaches – were lost to follow-up or were
not taking their medications regularly [4]. As for many low-
and middle-income countries, it is difficult to fully imple-
ment DOT management for the treatment of TB in China,
complicated by the high cost of healthcare and differences
in economic levels, geography, availability of transportation,
and patient preferences [3].
In response to the problems of implementing DOT,
current developments in treatment management involve
the utilisation of eHealth technology and research to
discover more effective and efficient ways of ensuring
that patients take their medication, as highlighted by the
WHO Global Task Force on Digital Health for TB [5].
The 2017 update to the WHO’s TB treatment guidelines
suggests that tracers (such as mobile phone short mes-
sage service (SMS)) and/or digital medication monitors
may be offered to patients on TB treatment and that
video-observed treatment (VOT) can replace DOT
under some circumstances [6]. However, both are condi-
tional recommendations with “very low certainty in the
evidence”. A systematic review of SMS use for promot-
ing adherence to TB medication found four studies with
a control group, of which only one was a randomised
controlled trial and this trial had only 37 patients [3, 7].
In our previous pragmatic, cluster-randomised trial, 36
districts/counties within four provinces of China were ran-
domised to one of four case-management approaches utilis-
ing SMS, a medication monitor, both, or neither (control)
[8]. Treatment adherence was the primary endpoint. The
intervention arms had reminders for drug intake, reminders
for monthly follow-up visits, and a recommendation to
switch patients with adherence problems to more intensive
management or DOT. The percentage of patient-months
on TB treatment where at least 20% of doses were missed
was 29.9% in the control arm, 27.3% in the SMS arm
(adjusted mean ratio (aMR) of 0.94, 95% confidence interval
(CI) 0.71–1.24), 17.0% in the medication monitor arm
(aMR 0.58, 95% CI 0.42–0.79), and 13.9% in the combined
arm (aMR 0.49, 95% CI 0.27–0.88). Patient loss to follow-
up was lower in all three intervention arms, but there was
only statistical evidence for this reduction in the SMS arm
(aMR 0.42, 95% CI 0.18–0.98). Equipment malfunction or
operation error was reported in all study arms. Based on
these results, the use of a medication monitor shows great
promise. A new, improved version of the medication
monitor has been developed [9], including generation of a
graphical display of a patient’s detailed dosing history at
monthly follow-up visits to facilitate discussion between
the patient and doctor. However, it remains to be seen
whether these improvements in adherence, and possibly
in retention, translate into meaningful improvements in
clinical outcomes.
The overall aim of the trial is to investigate whether
drug-sensitive pulmonary adult TB patients whose treat-
ment strategy includes a medication monitor for daily drug
dosing reminders and monitoring of adherence patterns,
together with targeted intensive management of patients
with poor adherence patterns (intervention arm), have bet-
ter clinical and adherence outcomes compared with pa-
tients managed according to standard of care (control arm).
Rationale for a randomised controlled trial
Although the first trial showed promising results, our
primary outcome was adherence to treatment and the rela-
tionship between adherence and clinical outcomes is likely
to be non-linear. We had included a secondary outcome of
poor treatment outcome, though the study was underpow-
ered for this and the outcome was based on routine data
collected at the end of treatment, which is considered a
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poor proxy for true cure of TB. The intervention has now
changed to include an explicit discussion of detailed dosing
history between patients and doctors as well as an im-
proved medication monitor. Although the improved medi-
cation monitor remains at low cost per patient, rolling this
out for almost one million TB patients annually would still
require a substantial financial investment and increased
training. Hence, strong evidence is needed that this would
lead to a substantial improvement in patient clinical out-
comes, which can best be obtained from a randomised con-
trolled trial.
Rationale for a cluster randomised trial
There is debate as to whether trials of health service deliv-
ery should be individually or cluster randomised [10, 11].
Cluster randomised trials require larger sample sizes than
comparable individually randomised trials due to the lack
of independence, and resulting intra-cluster correlation,
between observations within clusters. As they typically
randomise a much smaller number of units, cluster rando-
mised trials also have an increased chance of baseline im-
balance by study arm. However, if the intervention is to be
delivered at the level of a cluster (for example, a clinic or a
district), then the trial needs to be cluster randomised.
In this trial, all patient recruitment, follow-up and data
collection will be performed by routine staff and it is
thought to be substantially more complicated to request
that they also undertake randomisation of patients into two
trial arms. The intervention requires changes to delivery of
care, which will be easier to implement if intervention and
control patients are not both managed in the same clinic.
Under individual randomisation, patients treated in the
same clinic might discuss with other patients regarding the
adherence technology and the subsequent advice received
following discussion of detailed dosing history, both of
which would cause a dilution of the effect size. In addition,
staff might also change their behaviour and become more
likely to monitor and discuss adherence with patients
randomised to the control arm, thereby changing the usual
standard of care, also diluting the effect size. For these
reasons, we decided to randomise at the level of counties/
districts as this is the smallest level at which comprehensive
TB care is delivered (within China the distinction between
counties and districts as administrative areas is defined as
less than, or more than, half the population residing in an
urban area).
Hypothesis
We hypothesise that managing drug-sensitive pulmonary
adult TB patients using a treatment strategy that includes a
medication monitor with daily reminders of drug dosing,
monthly reminders for pharmacy refills, and the monitoring
of adherence patterns, as well as targeted intensive
management of patients with poor adherence patterns, will
result in better clinical and adherence outcomes.
Methods/design
Study design
This is a two-arm, unblinded, pragmatic, cluster rando-
mised superiority trial, with equal numbers of clusters
randomised to intervention and control arms. The unit of
randomisation will be counties/districts in three provinces
in China with the distinction between counties and dis-
tricts being one of degree of urbanisation.
Study setting
National TB Control Programme guidelines in China re-
quire drug-sensitive TB patients to take fixed-dose combin-
ation tablets daily for 6 months. Each county/district has
one designated hospital or TB dispensary in which patients
initiate TB treatment and then have monthly consultations
with a TB doctor to discuss side effects and adherence, and
to obtain the next month’s supply of tablets.
Intervention arm
Patients will be asked to keep their monthly supply of medi-
cation in the medication event reminder monitor (MERM),
which has three key functions: an audio and visual reminder
for patients to take their daily medication; reminds pa-
tients of upcoming monthly visits; and to record date and
time whenever the box is opened (Table 1; Fig. 1) [9]. The
MERM used in this study is the evriMED 500 (Wisepill,
Cape Town, South Africa). At the monthly follow-up visit,
their managing doctor downloads these data to a computer
system that generates a graphical display of the last month’s
adherence record, which doctors use to discuss adherence
issues with the patient and to decide whether to switch the
patient to more intensive management.
Standard of care
Patients, in consultation with the doctor, choose whether to
take their tablets under direct observation by a healthcare
worker, direct observation by a family member, or through
self-administration (Table 1). After each dose is taken, a
mark is put on a TB treatment record card, which is shown
to the doctor at the monthly follow-up visit as a way of
determining adherence.
Selection of study counties/districts
Counties/districts were selected from four prefectures
(Hangzhou, Weizhou, Jilin and Ganzhou) in three prov-
inces (Zhejiang, Jilin and Jiangxi) chosen to reflect a variety
of settings. Within these four prefectures, 24 counties/dis-
tricts were chosen with access to GeneXpert MTB/RIF and
culture facilities, at least 300 pulmonary TB patients treated
in 2014, implementing daily TB treatment in a TB-
designated hospital or TB dispensary, and that were willing
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to participate in this study and were not already participat-
ing in another study.
Study population
The study population comprises a consecutive sample of
adults (≥ 18 years) with a new episode of Gene Xpert-positive
and rifampicin-sensitive pulmonary TB. In order to maximise
generalisability, we plan to make the trial as inclusive as pos-
sible. However, the study procedures require that the patient
is likely to be in the study area for the 18 months following
inclusion in the study, receives daily fixed-dose combination
tablets, is not known at the start of treatment to need more
than 6 months of treatment or to be hospitalised for more
than 2 months, and is not known to be HIV positive.
Trial outcomes
The primary outcome is a composite poor outcome mea-
sured over 18 months from start of TB treatment, defined
Table 1 Description of intervention versus standard of care (control) arms
Service contents Intervention arm Control arm
Supervision
method for
daily dosing
Patient receives daily reminders for drug intake by the MERM
through a buzzer sound and green light, which are active for
5 min then silent for 5 mins, and then is repeated twice.
If the MERM is opened during this period, then the alarm is
cancelled until the next day. The time of the reminder is set
by the doctor at enrolment and can be changed at
subsequent follow-up visits.
Patients choose one of the three methods of adherence
supervision in consultation with their doctor at the start
of treatment: direct observation by (1) healthcare worker
or (2) family member; or self-administered.
Follow-up visit
reminder
A yellow light on the MERM is used to remind patients to
attend their monthly follow-up visit. The light comes on
daily, at an agreed time, for 30 mins, for 3 days before their
scheduled visit date.
A pictogram label on the MERM indicates that sputum should
be collected at clinic visits at 2, 5, and 6 months.
No reminder.
Pictogram labels are not used on the MERM for patients
in the control arm.
Monthly follow-up
patient visit to the
doctor
The TB doctor at the county (district) level exports data on date/
time of the box being opened from the MERM and a graphical
display of the dosing history for the last month is generated.
The doctor shows the graphical display to the patient, and
discusses the patient’s drug-intake summary and the
importance of timely drug-intake. A printed copy of graphical
display summary is given to the patient, where feasible.
Based on the MERM data from the last month, the doctor
determines whether an adjustment to the way of managing
patient medication is required. Actions are described below.
Patients are seen at the monthly follow-up visits by the
TB doctor at the county (district) level.
If the TB treatment record card indicates doses have been
missed, the doctor asks the patient about why drugs have
been missed and discusses the importance of timely and
regular drug intake.
The doctor does not have access to the MERM data.
Judgment and
handling of
missing doses
The doctor assesses adherence using data from the MERM,
excluding time periods when the patient had been in hospital
or travelling. If:
< 20% doses missed: reasons for doses missed are ascertained
and the patient educated about keeping healthy. No change
to the management of the patient.
20–50% doses missed (first occasion): Township doctors are
asked to visit the patient every 2 weeks and village doctors
are asked to visit the patient every week to support
medication adherence.
> 50% doses missed or 20–50% doses missed (second occasion):
management mode is changed to “taking medicine in the
presence of medical staff”, namely, village doctors are
required to directly supervise patients to take medicine daily.
No specific requirement.
Doctor to
patient visit
(1) The CDC doctor visits each patient once during the intensive
and continuous phases. At the visit, the patient's adherence and
the use of MERM is discussed. If the patient is reluctant to take
treatment, the reason is identified and information is given to
the patient on keeping healthy.
(2) Doctors from community service centres visit the patient once
a month to confirm use of the MERM and monitor adverse reactions.
Any errors in using the MERM or any serious adverse reactions are
immediately reported to the organisation for TB prevention at the
county (district) level.
Standard NTP practice:
(1) The CDC doctor visits each patient once during the
intensive and continuous phases. The doctor asks about
the patient’s drug adherence, gives advice about timely
and regular drug intake, and educates the patient about
keeping healthy.
(2) Doctors from community service centres visit patients
who are self-supervised/family member supervision every
10 days in the intensive phase, and once a month in the
continuous phase.
CDC Center for Disease Control, MERM medication event reminder monitor, NTP National Tuberculosis Programme
In both arms the following occurs:
If a patient does not attend the scheduled follow-up visit, the hospital/dispensary doctor, nurse or other staff member contacts the patient (using patient or family
member phone) and asks them to return to the hospital/dispensary for follow-up. If a patient does not attend a follow-up visit 3 days after the scheduled date,
the hospital/dispensary doctor informs the CDC, who in turn informs the village doctor. The village doctor is required to visit the patient and supervise them to
visit the designated medical institution to get medications or receive sputum examination within 24 h after receiving the follow-up notification
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as either of poor outcome at the end of treatment (death,
treatment failure or loss to follow-up) or subsequent recur-
rence (culture positive for TB at 12 or 18 months or re-
starting TB treatment in the follow-up period). Secondary
outcomes are three clinical outcomes and two adherence
outcomes: poor outcome at the end of treatment; compos-
ite poor outcome measured at 12 months; lost to follow-up
during treatment; percentage of months in which the pa-
tient missed at least 20% of doses, measured using data
from the MERM; and percentage of total doses missed.
Cost-effectiveness outcomes include mean cost per patient
treatment month for each arm, and incremental cost of the
intervention per patient completing treatment, per death
and per disability-adjusted life year averted.
Economic evaluation
An economic evaluation will be conducted from a societal
perspective, estimating the incremental cost per disability-
adjusted life year averted of MERM compared to the
standard of care. Data will be collected on two types of in-
cremental costs, namely (1) incremental costs of MERM
implementation and (2) incremental cost of TB treatment
in both MERM and the standard of care. Analysis will be
carried out in two stages. First, a within-trial analysis will
be conducted comparing cost-effectiveness within the trial
population and period, using statistical methods to esti-
mate the probability that the intervention is cost-effective.
The second stage will use a decision analytical model to
extend these results over time to include downstream
costs (such as the further treatment of recurrences).
Sample size considerations
Recently completed phase III TB treatment trials, con-
ducted under clinical trial conditions, found percentages
with poor outcome at end of treatment of 8.5% to 11.2%,
and by 18 months from enrolment ranging from 13.2% to
15.7%, in the control arm [12–14]. As these data were col-
lected under clinical drug trial conditions we would expect
poor outcomes to be higher in a pragmatic setting. Data
from our first adherence trial in China found a combined
poor outcome at the end of treatment of 9.2%. This was in
the absence of culture to define treatment success and it is
therefore reasonable to expect a higher risk of poor
outcome when using culture to define end of treatment
outcomes. Assuming 12 clusters per arm, 125 patients per
cluster, 5% of individuals whose outcome at 18 months
cannot be ascertained, a composite poor outcome es-
timate of 18% in the control arm, and taking account
of the clustered design using a coefficient of variation
of 0.25, there will be 92% power to assess a 40% reduc-
tion in poor outcome. In our first adherence trial
comparing the medication monitor arm to the stand-
ard of care arm, poor adherence was reduced by 42%
(95% CI 21–58% reduction) and poor treatment out-
come by 29% (95% CI 51% increase to 67% reduction);
therefore, a reduction of 40% should be achievable with an
improved intervention.
Randomisation
Unstratified, restricted randomisation was used to improve
baseline balance, as is common for cluster randomised
trials with a small number of clusters. The restrictions were:
within each of the four prefectures, the difference in num-
ber of intervention and control clusters should be at most
one; there should be seven clusters with a designated hos-
pital and five with a TB dispensary in each arm; the
difference in the number of intervention and control arm
clusters should be at most one in each of the seven urban
Fig. 1 Graphical illustration of the medication event reminder monitor (MERM) to be used in this trial (dimensions are: height 71.4 mm x width
129 mm x length 166.9 mm)
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and 17 rural clusters; and the difference in the average
number of smear-positive TB cases notified in each cluster
in 2015 between intervention and control arm clusters
should be at most 10 cases. Applying these criteria to
10,000 randomly generated allocations left 102 acceptable
allocations (1.02%), giving a restriction factor of 0.990 (95%
CI 0.988–0.992). Of 2,704,156 possible allocations, this left
approximately 27,582 acceptable allocations (95% CI
22,510–33,446). The proportion of 5000 randomly gener-
ated, acceptable allocations for which a pair of clusters were
in the same arm varied between 0.261 and 0.770, suggesting
that the most restrictive criteria would still allow for appro-
priate statistical inference. One of these 5000 acceptable
allocations was then chosen at random in Stata version 14
by the statistician (author JJL) and communicated in this
unblinded trial.
Study procedures
Consecutive adult patients starting TB treatment at the TB
dispensary/hospital in the county/district will be screened
by their treating doctor (as trained by the study team) and,
if eligible, offered enrolment in the study. Following
informed consent (see Additional file 1 for informed con-
sent form and patient information sheet), participants will
complete a questionnaire and be asked to give a sputum
specimen for smear microscopy and GeneXpert (see Fig. 2
for a summary of study procedures for intervention and
control arms), and Additional file 2 for completed SPIRIT
checklist).
Participants in both the intervention and control arms
will be given a MERM box and 30 days of medication,
which they will be asked to keep in the MERM. The box
records the date and time of each opening. Participants will
return to the TB dispensary/hospital for each of six
monthly follow-up visits (months 1–6). Patients in the
intervention arm will be required to bring their MERM to
each monthly follow-up visit, at which the doctor or desig-
nee will connect it to the computer and download the data.
In the control arm, the MERM is in silent mode (no audio
or visual reminders) and data from the box will be down-
loaded once, at the end of treatment or earlier if the patient
stops using the MERM before the end of treatment; the
doctor will not be able to access these adherence data. In
either arm, if applicable, the doctor or designee will assist
the patient to fix any problems with the box and, if neces-
sary, to replace it.
Sputum will be collected at the end of the second
month for an exploratory endpoint of 2-month smear
conversion and again at the end of treatment for culture
(using Lowenstein–Jensen) and smear to enhance the
definitions of treatment ‘cure’ and ‘failure’.
Following the end of treatment, the treatment outcome,
as recorded by the National TB Control programme, will
be abstracted. Patients will be seen at the TB hospital/
Fig. 2 SPIRIT figure – summary of study procedures for intervention and control arms
Lewis et al. Trials  (2018) 19:398 Page 6 of 12
dispensary at two further follow-up visits, at 12 and
18 months after start of treatment, for a chest x-ray and to
collect a sputum specimen for culture in order to measure
recurrence. Patients will also be asked about TB symptoms
and whether they have re-started TB treatment. The hos-
pital/dispensary doctor, nurse or other staff member
will help facilitate patient attendance at these post-
treatment follow-up visits. In addition, these patients
will be telephoned at months 9 and 15 after the start
of treatment and asked about TB symptoms and
whether they have re-started TB treatment. Patients
with TB symptoms will be advised to attend a health-
care clinic. If a patient has restarted TB treatment,
information from the TB register and TB diagnosis
will be abstracted.
Participants are free to withdraw from the study at any
time and those in the intervention arm can stop using the
MERM, whilst remain in the study, at any time. Partici-
pants will also be withdrawn from the study if they plan to
move away or travel continuously for more than 1 month,
or if they are no longer using daily fixed-dose combination
tablets. All participants who withdraw early will be asked
if we can still collect their treatment outcomes and con-
tact them for post-treatment follow-up. No other changes
to care are prohibited during the trial.
A pilot study enrolled 55 patients in four counties/dis-
tricts before commencing enrolment into the trial to
field test the MERM and associated software, the re-
cruitment process, the monthly adherence feedback
given to patients by the managing Doctor and case report
forms. Following the pilot study, all 24 counties/districts
had a 3-month run-in period to help staff familiarise
themselves with the recruitment and follow-up processes
and ensure all monitoring processes are being
implemented.
Data management
The treating doctors will be trained and responsible for
collecting written, informed consent, assessing eligibility,
and capturing all data into a bespoke database. A pass-
word will be required to gain access to the database. Data
will be validated on entry, using range and consistency
checks. Logical data checks will also be performed on the
data. Incomplete and incorrect data queries will be sent
back to sites electronically for error resolution. All study
records will be managed in a secure and confidential
fashion. All records will be stored at the participating TB
clinics and offices at provincial level in locked filing
cabinets and access to the records will be restricted to
specified study team members. Case report forms will be
identified using the participant’s study number only, with
locator information stored separately. When datasets are
generated for data analysis, personal identifiers will be
removed. All records will be archived in a secure storage
facility for at least 10 years after the completion of the
study.
Statistical analysis
Analyses will use an intention-to-treat approach with
methods appropriate for the clustered randomised trial
design, giving each cluster equal weight [10]. Quantitative
outcomes will be summarised as the mean for each cluster
and the difference of means for intervention versus stand-
ard of care arm. For binary outcomes or rate outcomes,
the overall risk (rate) for each cluster will be calculated as
well as the ratio for intervention versus standard of care
arm. An adjusted analysis will be conducted to control for
baseline imbalance of patient or district/county level
factors across control and intervention arms. Subgroup
analyses will be conducted for the primary outcome and
may include urban/rural, gender, literacy levels, migrant/
non-migrant and type of healthcare provider. A statistical
analysis plan will be finalised prior to the end of data
collection.
Ethics and dissemination
The trial has approval from the Institutional Review Board
of the Chinese Center for Disease Control and Prevention
(ref: 201603) and the London School of Hygiene &
Tropical Medicine Ethics Committee (ref: 10665). It is
registered with Current Controlled Trials (identifier
ISRCTN35812455). Participants in both intervention and
control arms will receive around 200 RMB (in total;
approximately US$30) if they attend for study review visits
at 12 and 18 months after enrolment, as compensation for
their time and travel expenses. In addition, all patients will
benefit from a free GeneXpert test at enrolment, allowing
quick diagnosis of drug resistance to rifampicin, as well as
free cultures at the end of treatment and at 12 and
18 months. Written, informed consent will be sought
from potential participants by their treating doctor (as
trained by the study team), using standard consent forms
and information sheets available in Chinese Mandarin.
The trial results will be communicated to stakeholders
through dissemination meetings. Investigators will present
results at relevant conferences and submit manuscript(s)
to peer-reviewed journals. Public access to the participant-
level dataset of main trial results and statistical code will
be made available.
Trial governance
Xiaoqiu Liu is the Chief Investigator and is employed by
the Chinese Center for Disease Control and Prevention,
which is the trial sponsor. The trial sponsor had no role in
the design of this study and will not have any role during
its execution, analyses, interpretation of the data, or
decision to submit results.
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The trial investigator team is responsible for the trial
design, leading the implementation, data analysis, publi-
cation, and determining authorship eligibility guidelines,
while a trial implementation team is responsible for site
training, study monitoring, auditing trial conduct in site
visits once every 3 months, and day-to-day implementa-
tion of the trial. A trial steering committee oversees the
trial, monitors its progress and provides advice to the
Chief Investigator and trial investigator team.
The trial does not have a Data Monitoring Committee, as
any potential harms to patients are thought to be low risk.
The Patient Information Sheet contains two telephone
numbers for the Principal investigator (author XL), in case
the patient wants to ask anything, and this is the primary
means by which patients can report problems with trial
conduct. The Trial Steering Committee will review progress
data and will thus partially function as a Data Monitoring
Committee. Recruitment will take approximately 2 years,
and for each individual in the study there will be a 6-month
treatment period followed by a further 12 months of
follow-up. At the time that recruitment ends, there will
only be primary outcome data for approximately a quarter
of participants. Hence, there is no planned interim analysis.
Any major changes to the study would be updated in the
protocol and trial registration, reported to the ethics com-
mittees for approval, and communicated to the trial steer-
ing committee at the next meeting.
Preliminary data from the run-in period
A 3-month run-in period was conducted in all 24 clusters.
TB patients recruited during this period will be followed
up at the end of treatment but not contribute to the trial
outcomes. Overall, 485 patients have been recruited, of
which 73% are male, median age 40 years (interquartile
range: 27–57 years), 7% are illiterate and 64% had smear-
positive TB (Table 2). Most characteristics were similar to
those observed in the first study, but patients in this study
were less likely to be living in their place of registration
(69% vs. 91%) and were more likely to have smear-positive
TB (64% vs. 36%).
Discussion
This large, pragmatic trial has been designed to determine
whether a new patient management model, based around
the MERM, results in improved clinical outcomes for TB
patients. The aim of the trial is to inform government
policy in China, and elsewhere, and is thus fundamentally
a study of effectiveness rather than efficacy. For this rea-
son, we have elected to conduct a highly pragmatic trial.
We have scored our trial using the PRagmatic Explanatory
Continuum Indicator Summary (PRECIS-2) tool, which
describes where a trial lies on the pragmatic/explanatory
continuum across nine domains [15]. Two authors (JL and
SS) scored the trial on each of the nine domains and
discrepancies were resolved by a third author (KF). The trial
scored as ‘very pragmatic’ on three domains, namely
‘recruitment’, ‘setting’ and ‘primary analysis’, and as ‘rather
explanatory’ on three domains, namely ‘eligibility’, ‘flexibility
– adherence’ and ‘follow-up’ (Fig. 3). The intervention is
applicable for almost all TB patients using fixed-dose
combination tablets, and so most of the eligibility criteria
result from the needs of the trial. The primary outcome is
measured over 18 months; therefore, we want to ensure that
participants are planning on staying in the area for the next
18 months. To ensure comparability between participants,
we also require them to be on treatment for the same
duration, namely 6 months. We want to ensure that all
participants have drug-sensitive TB to ensure the best
chance of impacting a clinical outcome. The intervention is
designed to maximise adherence to the intervention; thus,
we have scored the ‘flexibility – adherence’ domain as ‘rather
Table 2 Data from run-in period from the 24 clusters (n = 485)
Characteristic Category Number Percent
Gender Female 132 27.2%
Age, years 18–29 152 31.3%
30–39 87 17.9%
40–59 149 30.7%
60+ 97 20.0%
Farmer Yes 226 46.6%
Education, highest level Illiterate 36 7.4%
Primary School 134 27.6%
Junior Middle School 178 36.7%
High School
(Technical School)
81 16.7%
University or more 56 11.6%
Marital status Single 119 24.5%
First marriage 337 69.5%
Other 29 6.0%
Residency Place of registration 336 69.3%
Monthly household
expenditure, CNY
< 1000 58 12.0%
1000–3000 255 52.6%
3001–5000 132 27.2%
> 5000 40 8.3%
Distance to TB clinic, km 0–9 170 35.1%
10–29 203 41.9%
30–39 45 9.3%
40+ 67 13.8%
Distance to local village/
township doctor, km
0–1.9 247 50.9%
2–2.9 109 22.5%
3+ 129 26.6%
Smear status Positive 309 64.1%
Lewis et al. Trials  (2018) 19:398 Page 8 of 12
explanatory’, as suggested in the guidance [15]. All treating
doctors are trained on the study procedures, but we do not
enforce any aspect of the protocol, in line with the desire to
make the trial as pragmatic as possible. There are three
reasons why we scored ‘follow-up’ as ‘rather explanatory’;
firstly, our primary outcome requires a follow-up visit at 6
and 12 months after the end of treatment; second, we will
contact participants by telephone at 3 and 9 months after
the end of treatment to see if they have restarted TB
treatment; and finally, in some provinces, TB treatment now
requires clinic visits less than monthly, which we require in
the control arm. The average score across the nine domains
was 3.6, with 1 being ‘very explanatory’ and 5 being ‘very
pragmatic’.
Since the publication of the systematic review by Nglazi
et al. [7], two randomised controlled trials of an mHealth
intervention for TB have reported their results. An
individually randomised trial of a two-way SMS reminder
system in Pakistan, using an intervention similar to our
first trial, showed no impact on clinically recorded treat-
ment success (83% in intervention arm vs. 83% in control
arm) or self-reported medication adherence [16]. In
contrast, a cluster randomised trial of a one-way SMS
reminder system in China showed an improvement in
treatment completion (96% in intervention arm vs. 87% in
control arm), although the clustered design was not
accounted for in the analysis [17].
In Table 3, we summarise six ongoing randomised trials,
including our own, which are assessing eHealth interven-
tions to improve TB treatment-related outcomes and treat-
ment adherence. All trials were identified through a search
of trial registries. In addition to our study, two are assessing
VOT and three daily SMS reminders, total sample sizes
vary from 260 to 3000, and inclusion criteria are generally
very broad. Promisingly, all studies are measuring end-of-
treatment outcome, rather than solely adherence outcomes,
though not necessarily as the primary endpoint. However,
many of the studies are measuring end-of-treatment
outcomes using programmatic data. Treatment success
combines cure and treatment completion, but often the
programmatic data result in completion being the more
common of the two. Arguably, this provides poor quality
data on patient cure. Of note, ours is the only trial that we
are aware of that is using a clinical endpoint that includes
microbiological data from beyond the end of treatment, as
is common in trials of new TB regimens [12–14].
An important consideration in trials of new treatment
models for TB relates to the choice of control arm. The
control arm differs across the six ongoing trials, which
included three trials with DOT, one with a friend or family
supporter, one with self-administered treatment and our
trial, which uses standard-of-care as a mix of all three
options. It could be argued that the control arm should be
based on DOT, as recommended by the WHO. However,
as our aim is to provide evidence for policy, we decided to
make the pragmatic choice of using standard-of-care as
the control arm. If a rigorously implemented control arm
is based on DOT, then arguably such a trial should be
conducted as a non-inferiority trial, as it would be difficult
to improve on rigorously implemented DOT. In such a
trial, the aim would likely be to determine whether the
new treatment model is as good as (that is non-inferior
to) DOT, but presumably with a lower burden on the
health system. However, all of the published and ongoing
trials are being conducted as superiority trials, including
those directly comparing VOT to DOT.
Both this trial and our previous trial have randomised at
the cluster level, rather than at individual patient level, as
Fig. 3 Domain scores using the PRECIS-2 tool to determine where the trial lies on the pragmatic/explanatory continuum (1 = highly explanatory
to 5 = highly pragmatic)
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Table 3 Summary of ongoing randomised controlled trials of eHealth interventions for TB
Study
number1
Yr2 End
date
Country I/C3 Sample
size
Study
population
Intervention-eHealth
for adherence
Control Primary
outcome
Other relevant
outcomes
1 2017 2017 Kenya I 1200 Any age;
clinically
diagnosed
with TB by
smear
microscopy,
culture or
GeneXpert;
has access
to mobile
phone
Daily request for
self-verification
of drug intake;
Messages via
‘Keheala’ using
text message-like
interactions
Patients receive
medication for
1–2 w; assigned
a friend or family
member supporter
to verify the
patient’s drug
intake and return
to the clinic with
patient for refills
Unsuccessful
treatment
outcomes
–
2 2014 2017 Moldova I 400 18+ y; at
least 4 m
of care
remaining;
not homeless,
in prison,
alcoholic/drug
users, on
injectables
VOT – daily
observation
of drug intake
observed
via internet
video messages;
VOT observers
view and respond
to video messages
sent by patients
DOT – patient goes
to polyclinic to be
observed taking
treatment every
day
Adherence to
medication
Adherence
80%; treatment
success
(measured at
4 months);
side effects
reported during
treatment
3 2014 20154 Armenia C 380 18+ y;
diagnosed
with drug-sensitive
TB and completed
intensive phase
Daily SMS
reminders to TB
patients
DOT – observed
taking treatment
6 days/w by
healthcare
provider
TB treatment
success
(cured/
completed
treatment)
according
to WHO
definitions
TB treatment
adherence by self-
report
4 2013 20144 Cameroon I 260 18+ y; smear positive
pulmonary TB,
have a mobile
phone and able
to receive and
open SMS
Daily SMS
reminders to take
TB drugs; content
of messages
changes every 2
weeks
Patients attend
appointments
for drug supplies
weekly/monthly
in intensive phase
and monthly for
continuation phase;
SMS sent at start
and at end of
treatment
Treatment cure
(smear-negative)
at 6 m
Treatment
adherence
measured
by VAS and
appointments
attended at
2, 5, and 6 m;
treatment
failure at 5 m;
number of
patients who
develop
resistance
at 5 and 6 m
5 2014 2016 United
Kingdom
I 400 16+ y; any TB
patient from
participating
clinics who
is eligible
for DOT
VOT clips submitted
using a dedicated
smartphone with
a pre-loaded app;
VOT clips read by
a study nurse/VOT
observer daily
during weekdays,
weekend clips
read on Mondays
DOT – by clinic staff,
community-based
(responsible
professional:
hostel worker/
pharmacist)
or by outreach
worker; every day
or weekdays and
self-administered
at weekend
Proportion of
participants
having more
than 80% of
scheduled
VOT/DOT
sessions
successfully
completed
in the 2 m
following
randomisation
Proportion
of doses
observed
over 2 and
6 m; culture
conversion
at 2 m;
treatment
outcome
at 12 m
acquisition
of new
resistance; and
membership of
a transmission
cluster
6 2016 2019 China C 3000 18+ y; Xpert positive
(RIF sensitive),
on fixed dose
combination
Patients are provided
with MERM box with
reminding functions
(audio and light) for
(i) daily drug-intake
and (ii) attendance
of monthly follow-up
appointments
Standard of care –
self-administered,
family- or healthcare
worker-supported;
MERM in silent mode
Composite
unfavourable
outcome:
death, loss
to follow-up,
treatment
failure,
treatment
between
End of
treatment
outcomes;
adherence
outcomes
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has one of the five other ongoing trials summarised and
one other published trial [17] (Table 3). Randomising at the
cluster level has the obvious disadvantages of increased
sample size and increased possibility of allocation bias.
However, we felt that these were outweighed by the reduc-
tion in logistical complexity and reduction in possible con-
tamination between trial arms gained by randomising at
the level of the health system that treats patients (in China
this is at the county/district level).
Our trial will provide rigorous evidence of the impact of
a health system intervention based around a medication
monitor on clinical outcomes in China. Several other trials
are investigating the potential of other eHealth interven-
tions, making this an exciting time for the emerging
evidence base on eHealth interventions for TB. We believe
that our consideration of trial design issues presented in
this paper is a useful addition to the literature on evaluation
of eHealth interventions in this emerging field.
Trial status
The protocol is version 3.0, dated September 21, 2016. The
trial started recruitment to the run-in period on November
1, 2016, and to the main trial on January 16, 2017. Recruit-
ment to the main trial is ongoing and is expected to be
completed by December 31, 2018.
Additional files
Additional file 1: Informed consent form and patient information sheet.
(DOCX 33 kb)
Additional file 2: Completed SPIRIT checklist. (DOCX 59 kb)
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Table 3 Summary of ongoing randomised controlled trials of eHealth interventions for TB (Continued)
Study
number1
Yr2 End
date
Country I/C3 Sample
size
Study
population
Intervention-eHealth
for adherence
Control Primary
outcome
Other relevant
outcomes
the end of
treatment
and 18 m
after
enrolment
1Additional details of each study: (1) Trial registration at NCT03135366; intervention also includes access to a supporter via a chat client, and information
about TB. (2) Trial registration at NCT02331732. (3) Trial registration at NCT02082340; Trial protocol: Khachadourian et al. [18]. Intervention also includes the
following: (i) education and counselling session for drug-sensitive TB patients and their family members (90 min); (ii) self-administered drug intake supervised
by trained family member; (iii) daily phone calls to supporting family member; (iv) patients receive weekly SMS messages to attend the clinic weekly to receive
their medication; Cluster randomised – cluster is defined as a TB outpatient centre; 52 clusters in total. (4) Trial registration at PACTR201307000583416; Trial
protocol: Bediang [19]. (5) Trial registration at ISRCTN26184967. (6) Trial registration at ISRCTN35812455. Intervention also includes the doctor downloading the
monthly drug intake recorded from MERM and assessing how many doses have been missed, with patient. Based on the missed doses, additional interventions
are recommended to be implemented by the patient’s doctor such as additional visits from the township/village doctor; Cluster randomised – cluster is defined
as a county/district; 24 clusters in total
2Year trial was registered
3I/C individually (I) or cluster randomised (C)
4As reported in the trial registration
DOT directly observed treatment, m month, MERM medication event reminder monitor, RIF rifampicin, SMS short message service, TB tuberculosis, VOT
video-observed treatment, VAS visual analogue scale, w week, y years
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